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Background: The purpose of this study was to describe comorbidities, healthcare costs, and resource utilization
among patients with chronic non-infectious uveitis initiating corticosteroid, immunosuppressants, or biologics.
In this retrospective cohort study, patients with a non-infectious uveitis diagnosis and continuous insurance coverage
during a 6-month baseline were selected from a privately insured claims database with 80.7 million enrollees. Index
dates were defined as the first prescription/administration of a corticosteroid, immunosuppressant, or biologic
between 2003 and 2009. Comorbidities, healthcare costs, and utilization were analyzed in a per-member-per-month
(PMPM) framework to account for varying between-patient treatment periods, defined as continuous medication
use within the same class. Wilcoxon rank-sum and chi-square tests were used for comparisons of costs and
categorical outcomes.
Results: Patients on corticosteroids (N = 4,568), immunosuppressants (N = 5,466), and biologics (N = 1,694) formed
the study population. Baseline PMPM inpatient admission rates were 0.029 for patients on corticosteroids, 0.044
for patients on immunosuppressants, and 0.045 for patients on biologics (p < 0.001 immunosuppressants or
biologics versus corticosteroids); during treatment, PMPM inpatient admissions increased to 0.044 and 0.048 for
patients taking corticosteroids and immunosuppressants, respectively, but decreased to 0.024 for patients taking
biologics (p < 0.001 versus corticosteroids and p = 0.003 versus immunosuppressants). Baseline average PMPM
costs for patients taking corticosteroids, immunosuppressants, and biologics were US$935, US$1,738, and US
$1,439 (p < 0.001 between groups), while on-treatment PMPM costs excluding drug costs increased to US$1,129
for patients taking corticosteroids but lowered to US$1,592 for patients taking immunosuppressants, and US$918
for patients taking biologics (p < 0.001 versus corticosteroids or immunosuppressants).
Conclusions: There is significant economic burden associated with existing treatments of uveitis. Corticosteroids
may be overused as a treatment for uveitis.
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Uveitis is an inflammatory condition of the eye that is
typically characterized by redness, pain, light sensitivity,
and blurred/decreased vision and is associated with
numerous ocular diseases and systemic conditions.
This inflammation can also be categorized by the
location of inflammation, including anterior uveitis* Correspondence: chuda@njms.rutgers.edu
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in any medium, provided the original work is p(e.g., iritis), intermediate uveitis (e.g., pars planitis, vitri-
tis), and posterior uveitis (e.g., choroiditis, retinitis).
Anterior uveitis is the most common form of uveitis in
most populations, particularly in Western countries,
accounting for about 50% to 60% of all uveitis cases in
most tertiary referral centers and around 90% in pri-
mary care settings [1]. The majority of uveitis-related
visual morbidity occurs in patients with posterior segment
uveitis, which includes intermediate, posterior, and
panuveitis.
Uveitis is responsible for an estimated 10% of cases of
blindness in the USA [2,3], including 30,000 new casesopen access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Chu et al. Journal of Ophthalmic Inflammation and Infection 2013, 3:64 Page 2 of 10
http://www.joii-journal.com/content/3/1/64of legal blindness each year [4]. Uveitis is a major cause
of visual morbidity in the working age group [5]. Early
diagnosis and treatment are important to prevent the
vision-threatening complications of uveitis, including
cataract, glaucoma, retinopathy, and macular edema
[6]. Goals of treatment include suppressing inflamma-
tion and achieving remission [7].
Three drug classes that constitute the primary treat-
ment modalities for uveitis include corticosteroids,
traditional (non-biologic) immunosuppressive agents,
and biologics. Corticosteroids are typically used as
the first-line drug therapy for non-infectious inflamma-
tory conditions [8]. They may be used topically, adminis-
tered systemically via oral, intravenous or intramuscular
route, or injected periocularly or implanted surgically.
Serious side effects such as hypertension, cardiac failure,
weight gain, osteoporosis, myopathy, osteonecrosis, and
gastrointestinal side effects [9] are associated with the
chronic use of systemic corticosteroids. If a patient's
uveitis is not completely quiet after several weeks of
high-dose corticosteroids and maintained with 10% mg
per day of prednisone (or equivalent) within 3% months
or if the posterior segment is being affected, established
guidelines recommend the use of steroid-sparing agents
[10], such as second-line traditional immunosuppressant
therapy (i.e., antimetabolites, T cell inhibitors and alky-
lating agents) [8,11].
For patients whose uveitis condition is refractory to
traditional immunosuppressants, biologic therapies may
be considered. Examples of biologics used as a third-
line therapy include tumor necrosis factor (TNF) in-
hibitor agents, such as infliximab and adalimumab; in-
terferons, such as recombinant human IFN-α-2a and
IFN-α-2b; and anti-interleukin therapy [12]. Even though
there have been a large number of reports on the use of
biologic therapies to treat uveitis, there have been no
controlled trials comparing the efficacy of different bio-
logic therapies with each other or with traditional im-
munosuppressants, and further research is needed to
support clinical decisions regarding choice of agent,
time of initiation, and course of therapy [12].
Claims data analyses provide large samples for empir-
ical analyses, which could contribute to understanding
the economic burden related to uveitis as well as indica-
tors for ophthalmologic comorbidities. Previous re-
search has examined the incidence and prevalence of
uveitis in a privately insured population in Northern
California and Medicare populations [13,14]. Gritz and
Wong [13] found that the incidence of uveitis was
higher than results from smaller previous studies, the
prevalence increased with age, and women had a higher
prevalence of uveitis than men. Reeves et al. [14] found
that the burden of uveitis is higher in an elderly popula-
tion than previous research had indicated.In comparison to previous studies, the current study
utilizes pharmacy and non-elderly claims excluded in
the analysis by Reeves et al. [14] and includes a larger
sample to describe disease burden related to and treatment
patterns for patients receiving treatment for uveitis.
Specifically, we examine baseline characteristics, uveitis-
related ophthalmologic outcomes, healthcare utilization,
and healthcare costs among patients receiving the three
treatment options (i.e., corticosteroids, immunosuppressive
agents, and biologics) with non-infectious uveitis in a
privately insured population. We use a large, longitudinal
claims data as an efficient way to study uncommon
diseases like non-infectious uveitis [15].
Methods
Data and study design
The Thomson Reuters MarketScanW Commercial Data-
bases, which have been used previously to estimate the
economic burden of ophthalmologic disease [16], was used
in this analysis. This database contains individual-level
claims and enrollment data for approximately 80.7 million
members from January 2003 to October 2009. The data
include the enrollment history, demographics, medical
claims, and pharmacy claims for employees, dependents,
and retirees in the USA with primary insurance coverage.
We used a retrospective cohort design to address our
research questions. Retrospective cohorts using claims
data can provide equally valid results as a prospective
cohort study while being more economical [17].
Patient selection
Prior literature was used to identify codes for non-
infectious uveitis using the International Classification
of Diseases, Ninth Revision, Clinical Modification (ICD-9-
CM) coding system. Diagnosis codes including both
posterior and anterior disease were used in the base
case (Additional file 1: Table S1 for a complete list of
ICD-9-CM codes). In a sensitivity analysis, codes more
specific to posterior disease were used.
Patients were included in the sample if they had at
least one claim for non-infectious uveitis diagnosed by an
ophthalmologist (or optometrist) or two claims diagnosed
by other physician specialists. Patients were also required
to have at least one prescription dispensing or administra-
tion of corticosteroids, immunosuppressants, or biologics
on or after their diagnosis of non-infectious uveitis (the
list of drugs included can be found in Additional file 1:
Table S2). In order to exclude patients with post-surgical
inflammation, patients with incisional intraocular surgery
within 3% months of their uveitis diagnosis were excluded.
Patients were also required to have at least 6% months
of continuous insurance coverage prior to their first
prescription or administration, which was considered
their baseline period, as well as at least 10% days of
Chu et al. Journal of Ophthalmic Inflammation and Infection 2013, 3:64 Page 3 of 10
http://www.joii-journal.com/content/3/1/64study period drug use. In order to identify patients with
chronic uveitis, patients receiving corticosteroids had
to have continuous prescriptions for 60 or more days.
Sensitivity analyses requiring 90 or 30 or more days were
implemented. Patients over 65% years of age were excluded
from the analysis to avoid incomplete claims due to
Medicare dual coverage. Figure 1 contains additional
detail on patient selection.
Three samples were developed, including patients
receiving their first dose of corticosteroid therapy only
(CTS), traditional immunosuppressants/immunomodula-
tors (IMS) with or without corticosteroids, and biologics
(BIO) with or without corticosteroids or immunosuppres-
sants. Patients' first date of therapy was considered their
index date. Additionally, patients were required to have
no evidence of their sample's respective drug therapy in
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Figure 1 Sample selection criteria and sample development.Patient gender, age, health insurance type, and index
year were reported. To ascertain general comorbidity
burden of the patients at baseline, we used the Deyo
adaptation of the Charlson comorbidity index, excluding
ophthalmologic diagnosis codes [18].
Treatment periods
Analyses were performed based on treatment periods,
which form the study period in the analysis. Treatment
periods were defined as the continuous on-therapy
period for each patient within the same class, spanning
from a patient's index date to the date of either stopping
therapy, stepping up therapy, or being censored in the data
(e.g., disenrollment from health plan). Stopping therapy
was based on the patient not refilling the prescription for
a period of days equal to 150% the number of days in the
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on the literature for physician-administered intramuscular
injectables and infusions [12]. For example, if a patient
received a first prescription of prednisone on 01 April
2007 with a 30% days' supply, then a second 30-day
script on May 16 (which is a treatment gap of 15% days
or 50% of the days’ supply of the preceding script), and
then no further prescriptions, a steroid episode of 30 +
15 + 30% days would be assumed.
Stepping up therapy ended a treatment episode and
occurred on the day that a patient received a prescription
or administration for a higher class of therapy (e.g.,
from corticosteroids to immunosuppressants or immu-
nosuppressants to biologics). Switching within the same
class (e.g., from one immunosuppressant agent to another)
did not end a treatment episode.
Outcomes
Healthcare costs and utilization were measured in a
per-member-per-month (PMPM) framework to standardize
estimates across patients with treatment periods of different
lengths. Fractional months were grossed up to complete
months based on a patient's observed treatment days.
Healthcare costs were measured using the paid amount
by insurers for patient's covered benefits. Categories of
costs include costs related to inpatient care, emergency
room (ER) care, office or outpatient (OP) care, and care
for each type of therapy. Costs were inflation adjusted
to 2009 dollars based on the medical consumer pricing
index. Utilization was measured in terms of monthly
inpatient stays per patient and inpatient days per hospi-
talized patient, number of ER visits, number of OP visits,
and number of prescription drug scripts.
Kaplan-Meier analysis was used to assess time to aug-
ment or switch to a next-step class of therapy. Augmenting
therapy was considered to be adding a new class of therapy
before the current treatment episode had ended. Switching
therapy was based on beginning a new class of therapy
at any time observable in the data before a censoring
event, including loss of eligibility or the last available
data in September 2009.
Though not a primary focus of the analysis, ophthal-
mologic outcomes in terms of counts of diagnoses codes
for retinal detachments (ICD-9-CM codes: 361.0-361.3,
361.8, 361.9), glaucoma (ICD-9-CM codes: 365.0-365.6,
365.8, 365.9), cataracts (ICD-9-CM codes: 366.0-366.5,
366.8, 366.9), cystoid macular degeneration (ICD-9-CM
362.53), visual disturbances (ICD-9-CM codes: 368.1,
368.3-368.6, 368.8, 368.9), blindness (ICD-9-CM codes:
369.0-369.4, 369.6-369.9), and other visual complications
including phthisis bulbi, chorioretinal scars, other macular
scars, optic atrophy, optic neuritis, other disorders of optic
nerve, hypotony, and band-shaped keratopathy (ICD-9-
CM codes: 360.4, 363.3, 363.32, 377.1, 377.3, 377.4, 360.3,and 371.4) were also reported. Additional file 1: Table S3
contains additional detail.
Sensitivity analysis
Comparison of baseline and study period all-cause costs
were made for the CTS, IMS, and BIO samples excluding
patients with rheumatoid arthritis, Crohn's disease, psoria-
sis, or ankylosing spondylitis based on their ICD-9-CM
diagnosis codes in the baseline or study period. Patients
with these conditions may receive any of these treatments,
so we excluded them in a sensitivity analysis.
Posterior uveitis may be more severe than anterior
disease, though some codes may describe both types of
disease. In a second sensitivity on all-cause costs, we
include patients using a subset of ICD-9-CM codes that
are more specific to posterior disease (see Additional
file 1: Table S1). Lastly, we also assessed results excluding
diagnoses made only by non-ophthalmologists in order
to increase the accuracy of the non-infectious uveitis
diagnosis.
Statistical analysis
All analyses were conducted using SAS version 9.2 (SAS
Institute Inc., Cary, NC, USA). Statistical comparisons
were conducted using chi-square tests for categorical
outcomes and Wilcoxon rank-sum tests for continuous
outcomes within baseline and study periods. Wilcoxon
signed-rank tests assessed differences in pre- versus post-
comparisons.
Results
The distribution of the study population was 38.9%
CTS (N = 4,568), 46.6% IMS (N = 5,466), and 14.4% BIO
(N = 1,694) out of 11,728 patients. The study periods were
16,574, 20,308, and 12,940 patient-months for the CTS,
IMS, and BIO groups. Approximately 93% of the CTS
were (65,271 of 70,163) patients excluded from the
CTS sample as a result of patients having fewer than 60
continuous days of corticosteroids prescriptions.
As shown in Table 1, about 84% (9,808 of 11,728 total
patients) of patients were between age 35 and 64 at their
index date. A higher proportion of women receive IMS
(72.1%, 3,940 of 5,466 IMS patients) than BIO (61.4%,
1,040 of 1,694 BIO patients) or CTS (59.7%, 2,729 of
4,568 CTS patients) (p < 0.0001 for IMS versus CTS or
BIO). CTS patients were more likely to be enrolled in an
HMO (p = 0.0001 for CTS vs. IMS; p = 0.0004 for CTS
versus BIO). The numbers of patients diagnosed has
grown over time, with 2009 reflecting only 9% months of
available data. Between therapies, there were no apparent
trends related to the year in which therapy was prescribed.
In other words, neither IMS nor BIO therapy shows an
increase in the rate of use for patients fitting the selection
criteria over the period from 2003 to 2009.
Table 1 Baseline demographics for non-infectious uveitis
patients by treatment groups
CTS patientsa IMS patientsb BIO patients
(N = 4,568) (N = 5,466) (N = 1,694)
Gender, N (%)
Male 1,839 (40.3%) 1,526 (27.9%)a 654 (38.6%)b
Female 2,729 (59.7%) 3,940 (72.1%)a 1,040 (61.4%)b
Age, N (%)
0–17,% 162 (3.5%) 350 (6.4%)a 153 (9.0%)a,b
18-24 142 (3.1%) 170 (3.1%)a 77 (4.5%)a,b
25-34 305 (6.7%) 388 (7.1%)a 173 (10.2%)a,b
35-44 704 (15.4%) 868 (15.9%)a 390 (23.0%)a,b
45-54 1,360 (29.8%) 1,683 (30.8%)a 472 (27.9%)a,b
55-64 1,895 (41.5%) 2,007 (36.7%)a 429 (25.3%)a,b
Index year, N (%)
2003 175 (3.8%) 219 (4.0%) 72 (4.3%)
2004 401 (8.8%) 507 (9.3%) 151 (8.9%)
2005 641 (14.0%) 723 (13.2%) 208 (12.3%)
2006 730 (16.0%) 803 (14.7%) 250 (14.8%)
2007 862 (18.9%) 1,088 (19.9%) 346 (20.4%)
2008 1,063 (23.3%) 1,280 (23.4%) 420 (24.8%)
2009 696 (15.2%) 846 (15.5%) 247 (14.6%)
Health insurance type, N (%)
HMO 924 (20.2%) 924 (16.9%)a 282 (16.6%)a
PPO 2,456 (53.8%) 3,216 (58.8%)a 1,014 (59.9%)a
EPO 18 (0.4%) 34 (0.6%)a 7 (0.4%)a
Indemnity 72 (1.6%) 94 (1.7%)a 29 (1.7%)a
Other 1,098 (24.0%) 1,198 (21.9%)a 362 (21.4%)a
HMO, health maintenance organization; PPO, preferred provider organization;
EPO, extended provider organization. Chi-square tests were used to test
differences in categorical variables. a,bData with superscripted letter(s) indicate
a significant difference (P < 0.05) from the uveitis subtype represented by
that letter.
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ating therapy, BIO and IMS patients were associated
with the highest Charlson comorbidity index score. IMS
patients were associated with the highest level of glau-
coma, cataracts, and visual disturbances. Both IMS and
BIO patients had greater baseline rates of cystoid macular
degeneration than did CTS patients.
Small proportions of CTS patients had evidence of
prior IMS (6.1%, 280 of 4,568 CTS patients) or BIO
(2.5%, 112 of 4,568 CTS patients) use before their index
CTS dose, indicating that the sample was not completely
naïve to therapy. Most IMS patients received steroids
(69.2%, 3,784 of 5,466 IMS patients), and some IMS
patients had received biologics (5.7%, 313 of 5,466 IMS
patients). Most BIO patients had received steroids
(71.8%, 1,217 of 1,694 BIO patients), and more than
one-third received IMS (38.5%, 652 of 1,694 BIOpatients). These treatment patterns are consistent with
step therapy, where fewer patients advance to higher
levels of therapy.
During the baseline period, IMS patients were associ-
ated with the highest monthly all-cause costs (US$1,738
per month) followed by BIO (US$1,439) and CTS patients
(US$935) (p < 0.0001 between each). Inpatient costs
represented approximately 31.5% (US$294 of US$935),
39.8% (US$692 of US$1,738), and 28.4% (US$408 of US
$1,439) of total costs in the CTS, IMS, and BIO
samples.
Monthly rates of hospitalization and emergency room
visits in the 6%months prior to initiating therapy were
significantly different among the therapy groups. In terms
of patients who had any inpatient stay, BIO patients
were associated with the highest proportion of patients
hospitalized per month (2.3%, 39 of 1,694 BIO patients),
followed by IMS patients (2.1%, 114 of 5,466 IMS pa-
tients) and CTS patients (1.4%, 64 of 4,568 CTS patients)
(p < 0.0001 for IMS and BIO versus CTS). BIO patients
were associated with the highest proportion of patients
going to the ER per month (2.7%, 46 of 1,694 BIO patients)
followed by IMS patients (2.4%, 132 of 5,466 IMS patients)
and CTS patients (2.0%, 89 of 4,568 CTS patients).
Though not a primary focus of our analysis, ophthalmo-
logic comorbidities per patient in the study period are
presented in Table 3. CTS patients were associated with a
higher level of diagnoses of glaucoma, cystoid macular
degeneration, and retinal detachments compared to IMS
or BIO. CTS patients were also associated with a higher
level of visual disturbances compared to IMS. Incidence of
claims among CTS patients increased in the study period
relative to the baseline in glaucoma, cystoid macular
degeneration, retinal detachments, and visual disturbances;
however, incidence of claims among IMS and BIO patients
decreased or remained about the same in every category
except for glaucoma, where it increased for both.
In the study period, most CTS patients (72%, 3,288 of
4,568 CTS patients) neither augmented nor switched to
IMS or BIO, and most IMS patients (82%, 4,505 of 5,466
IMS patients) neither augmented nor switched to BIO.
Study period utilization and costs appear in Table 4.
As shown in Table 2, CTS patients were associated with
the lowest number of monthly ER visits and inpatient
stays per patient in the 6% months prior to their index
date. In the study period, IMS patients were had the high-
est number of inpatient stays per patient. BIO patients
had the highest number of inpatient stays and ER visits at
baseline. However, in the post-index period, BIO patients
had the lowest number of inpatient stays or ER visits. The
BIO group was the only group to have a reduction in
both the number of inpatient stays and ER visits. Monthly
inpatient stays decreased by 0.021 (p = 0.0033) stays per
patient and ER visits decreased by 0.012 (p = 0.0031)
Table 2 Baseline ophthalmologic comorbidities, utilization, costs, and prior therapy for patients with non-infectious
uveitis by treatment group
CTS patientsa IMS patientsb BIO patients
(N = 4,568) (N = 5,466) (N = 1,694)
Patient months 27,408 32,796 10,164
Baseline monthly ophthalmologic comorbidities, mean (std)
Glaucoma 0.041 (0.15) 0.045 (0.16) 0.028 (0.13)a,b
Cataract 0.022 (0.09) 0.024 (0.10) 0.016 (0.08)a,b
Cystoid macular degeneration 0.004 (0.03) 0.008 (0.06)a 0.008 (0.07)a
Retinal detachments 0.006 (0.05) 0.007 (0.06) 0.005 (0.06)a,b
Visual disturbances 0.005 (0.04) 0.007 (0.05)a 0.006 (0.05)
Blindness 0.001 (0.02) 0.002 (0.02)a 0.002 (0.02)a
Other visual complications 0.012 (0.06) 0.024 (0.11)a 0.019 (0.11) b
Baseline Charlson Comorbidity Index (CCI), mean (std) 0.482 (1.06) 0.730 (1.29)a 0.802 (1.15)a,b
Baseline monthly comorbidities, mean (std)
Crohn's disease 0.009 (0.10) 0.024 (0.22)a 0.086 (0.43)a,b
Rheumatoid arthritis 0.010 (0.09) 0.036 (0.18)a 0.125 (0.33)a,b
Psoriasis 0.005 (0.10) 0.017 (0.18)a 0.054 (0.31)a,b
Ankylosing spondylitis 0.005 (0.06) 0.013 (0.10)a 0.095 (0.23)a,b
Baseline monthly total healthcare costs, mean [median] (std) (US$) 935 [279] (2,840) 1,738 [492] (5,763)a 1,439 [597] (3,171)a,b
Medical services 735 [134] (2,741) 1,497 [288] (5,668)a 1,204 [375] (3,039)a,b
Inpatient stay (IP) 294 [0] (2,177) 692 [0] (4,816)a 408 [0] (2,233)a
Emergency room (ER) 18 [0] (119) 24 [0] (142)a 26 [0] (113)a,b
Office/outpatient (OP) 423 [123] (1,041) 782 [263] (1,787)a 771 [337] (1,528)a,b
Pharmacy services 200 [66] (453) 241 [87] (483)a 234 [104] (485)a,b
Corticosteroids 0 [0] (0) 3 [0] (9)a 3 [0] (11)a
Immunosuppressants 9 [0] (82) 0 [0] (0)a 20 [0] (104)a,b
Biologics 24 [0] (193) 48 [0] (271)a 0 [0] (0)a,b
Baseline monthly total healthcare resource utilization
Inpatient stay (IP)
Number of patients, N (%) 64 (1.4%) 114 (2.1%)a 39 (2.3%)a
Number of stays/patient, mean (SD) 0.029 (0.19) 0.044 (0.22)a 0.045 (0.19)a
Number of days/ hospitalized patient, mean (SD) 3.88 (8.05) 4.133 (5.76) 3.908 (4.03)a
Emergency room (ER)
Number of patients, N (%) 89 (2.0%) 132 (2.4%)a 46 (2.7%)a
Number of visits/patient, mean (SD) 0.028 (0.10) 0.035 (0.11)a 0.042 (0.12)a
Office/outpatient (OP)
Number of patients, N (%) 722 (15.8%) 900 (16.5%)a 281 (16.6%)a,b
Number of visits/patient, mean (std) 1.426 (1.48) 2.172 (1.82 )a 2.372 (1.82)a,b
Baseline treatment characteristics (over the 6 month period), N (%)
Baseline any corticosteroid use – 3,784 (69.2%)a 1,217 (71.8%)a,b
Baseline any immunosuppressant use 280 (6.1%) – 652 (38.5%)a,b
Baseline any biologic use 112 (2.5%) 313 (5.7%)a –
CTS, corticosteroids; IMS, immunosuppressive therapy; BIO, biologics. Chi-square tests were used to test differences in categorical variables. Wilcoxon tests were
used to test differences in continuous variables. a,bData with superscripted letter(s) indicate a significant difference (P < 0.05) from the uveitis subtype represented
by that letter.
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Table 3 Study period ophthalmologic comorbidities and prior treatment for patients with non-infectious uveitis by
treatment group
CTS patientsa IMS patientsb BIO patients
(N = 4,568) (N = 5,466) (N = 1,694)
Patient months 16,574 20,308 12,940
Mean months/treatment episode (time to discontinuation), mean (std) 3.63 (3.13) 3.72 (5.61)a 7.64 (9.36)a,b
Study period ophthalmologic comorbidities, mean (std)
Glaucoma 0.058 (0.22) 0.052 (0.22)a 0.034 (0.14)a
Cataract 0.022 (0.12) 0.025 (0.11) 0.016 (0.07)
Cystoid macular degeneration 0.013 (0.10) 0.010 (0.07)a 0.005 (0.04)a
Retinal detachments 0.011 (0.10) 0.004 (0.05)a 0.002 (0.03)a
Visual disturbances 0.007 (0.07) 0.004 (0.04)a 0.003 (0.02)
Blindness 0.001 (0.03) 0.002 (0.03) 0.000 (0.01)
Other visual complications 0.011 (0.09) 0.015 (0.12) 0.007 (0.05)
Augmenting or switching
Augmented to immunosuppressants, N (%) 348 (7.60%)
Mean days to augmenting, conditional on augmenting, mean (std) 57 (56)
Augmented to biologics, N (%) 96 (2.10%) 346 (6.30%)
Mean days to augmenting, conditional on augmenting, mean (std) 42 (37) 78 (116)a
Switched to immunosuppressants, N (%) 615 (13.50%)
Mean days to switching, conditional on switching, mean (std) 213 (299)
Switched to biologics, N (%) 221 (4.80%) 615 (11.30%)
Mean days to switching, conditional on switching, mean (std) 256 (358) 213 (295)
CTS, corticosteroids; IMS, immunosuppressive therapy; BIO, biologics. Chi-square tests were used to test differences in categorical variables. Wilcoxon tests were used to test
differences in continuous variables. a,bData with superscripted letter(s) indicates a significant difference (P< 0.05) from the uveitis subtype represented by that letter.
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http://www.joii-journal.com/content/3/1/64visits per patient from baseline to the study period for
the BIO group; however, inpatient stays increased by
0.015 (p = 0.0014) and 0.004 (p = 0.0007) stays per patient
for the CTS and IMS groups. ER visits increased slightly
by 0.002 (p = 0.0024) for CTS and decreased by 0.004
(p < 0.0001) for IMS.
In the study period, BIO patients were associated
with the highest monthly total healthcare costs. While
all-cause monthly healthcare costs during the study
period increased considerably from baseline in the BIO
group (+US$1,250, p < 0.0001) compared to the CTS
(+US$209, p < 0.0001) and IMS (+US$21, NS, p = 0.1075)
groups, relatively sizable reductions in inpatient costs
versus baseline occurred in the IMS (−US$256, p < 0.0001)
and BIO groups (−US$225, p = 0.0033). All-cause monthly
costs in the study period excluding study drugs were
lowest in the BIO group. Differencing these costs versus
the baseline resulted in cost increases in CTS (+US$194,
p < 0.0001) and decreases in IMS (−US$146, p < 0.0001)
and BIO (−US$521, p < 0.0001).
In sensitivity analysis requiring 90 (N = 2,341) or 30
(N = 19,426) days or more of continuous corticosteroid
use to be in the CTS sample, all-cause monthly costs
excluding study drugs increased + US$97 (p = 0.0002)
and + US$257 (p < 0.0001) in CTS.When excluding patients with rheumatoid arthritis,
Crohn's disease, psoriasis, or ankylosing spondylitis, base-
line and study costs were generally consistent with the
overall analysis. Average costs excluding study drugs in the
CTS (N = 4,169) sample increased (+US$226, p < 0.0001);
in the IMS (N = 4,287) sample, they increased slightly (+US
$56, p < 0.0001), and in BIO (N = 524), they decreased
(−US$841, NS, p = 0.3519).
When using ICD-9-CM diagnosis codes more specific
to posterior disease, average cost differences excluding
study drugs between study and baseline periods increased
(+US$176, p < 0.0001) in the CTS (N = 1,979) sample;
increased (+US$133, p < 0.0001) in the IMS (N = 2,465)
sample, and decreased (−US$768, p = 0.0152) in the BIO
(N = 672) sample.
Lastly, when excluding patients who were not diag-
nosed by an ophthalmologist in order to increase the
accuracy of the non-infectious uveitis diagnosis, base-
line and study costs were also generally consistent
with the overall analysis. Average costs excluding
study drugs increased (+US$228, p < 0.0001) in the
CTS (N = 3,732) sample; decreased slightly (−US$178,
p < 0.0001) in the IMS (N = 4,144) sample; and
decreased (−US$567, p < 0.0001) in the BIO sample
(N = 1,323).
Table 4 Study period utilization and costs for patients with non-infectious uveitis by treatment group
CTS patientsa IMS patientsb BIO patients
(N = 4,568) (N = 5,466) (N = 1,694)
Total monthly healthcare resource utilization per patient, mean (SD)
Inpatient stay (IP)
Number of stays/patient 0.044 (0.34) 0.048 (0.30) 0.024 (0.19)a,b
Number of days/ hospitalized patient 3.678 (3.89) 3.621 (4.18) 3.862 (3.68) b
Emergency room (ER)
Number of visits/patient 0.030 (0.13) 0.030 (0.13) 0.030 (0.13)a,b
Office/outpatient (OP)
Number of visits/patient 2.025 (1.81) 2.365 (1.95) 1.939 (1.55)
Pharmacy services
Number of scripts/patient 3.015 (2.36) 4.106 (2.93)a 3.389 (2.66)a,b
Total monthly healthcare costs per patient, mean [median] (SD) (US$) 1,144 [382] (3,601) 1,759 [484] (5,474)a 2,689 [2,194] (2,912)a,b
Medical services (excluding study drugs) 902 [195] (3,445) 1,324 [196] (5,194) 716 [273] (2,005)a,b
Inpatient stay (IP) 307 [0] (2,497) 436 [0] (3,891) 183 [0] (1,444)a,b
Emergency room (ER) 21 [0] (148) 25 [0] (277)a 21 [0] (373)a,b
Office/outpatient (OP) 574 [185] (1,720) 863 [186] (2,482) 512 [252] (1,110)a,b
Pharmacy services (excluding study drugs) 227 [82] (576) 268 [85] (538) 201 [87] (398)
Total study drug costs 16 [7] (26) 167 [64] (380)a 1,772 [1,491] (1,532)a,b
Total costs excluding study drug costs 1,129 [365] (3,599) 1,592 [379] (5,383) 918 [466] (2,105)a,b
CTS, corticosteroids; IMS, immunosuppressive therapy; BIO, biologics. Chi-square tests were used to test differences in categorical variables. Wilcoxon tests were
used to test differences in continuous variables. Healthcare costs and visits were calculated per-member-per-month (PMPM). Sample means and standard devia-
tions were weighted by treatment months. a,bData with superscripted letter(s) indicates a significant difference (P < 0.05) from the uveitis subtype represented by
that letter.
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Little is known about the actual practice patterns of physi-
cians treating uveitis. Our approach, using a retrospective
analysis of a large claims data set, has advantages over
previous research, which has generally relied on smaller
samples that are often focused on the elderly, tertiary
care centers, or a limited community population. Previous
research has found that the types of cases seen in tertiary
care centers or over limited geographies can vary based
on disease etiology and anatomic location, limiting their
generalizability [20]. Case series reports from subspecialty
practices may not reflect what general ophthalmologists
see and treat. The current study utilizes health insurance
claims data from about one-quarter of the US population
who are geographically diversely distributed and are cared
for by hospital and community doctors alike, including
inflammatory disorder ophthalmologists, general ophthal-
mologists, and other types of providers.
Findings indicate that the financial burden of chronic
non-infectious uveitis is comparable to other medically
and economically significant disease. Costs of treated
patients with uveitis in the baseline and study periods
were high for all groups relative to the average privately
insured patient, whose average monthly (annual) spending
in the USA was US$323 (US$3,868) in 2009 dollars [21].
Comparative study period costs per month in 2009 dollarsfor CTS, IMS, and BIO patients were US$1,144, US
$1,759, and US$2,689, respectively. After taking into
account healthcare cost inflation, we estimated that the
average cost for non-infectious uveitis patients ranges
from 3.1 to 8.3 times the costs of the average privately
insured patient in 2009. These observed mean monthly
healthcare costs for non-infectious uveitis are similar or
higher than those for diabetes or hypertension patients
(US$1,016 or US$723 in 2009 dollars) [22] in a privately
insured population and similar or lower than those for
cancer patients (US$2,649 for prostate cancer to US$9,225
for pancreatic cancer in 2009 dollars) in a private and
Medicare population [23].
In this study, a substantial proportion of chronic uveitis
patients received CTS alone, and a substantial majority
of these patients were never observed to switch to IMS
or BIO. While the CTS may have resolved the uveitis
for some patients, average costs, utilization and rates of
ophthalmological comorbidities increased during the CTS
treatment episodes, indicating evidence of increased disease
burden. Similar findings were evident in the sensitivity
analyses requiring 90 or 30% days of continuous corticoste-
roids to be included in the CTS sample; in the latter sensi-
tivity, N= 19,426 patients received CTS, 88% of whom had
no evidence of receiving immunosuppressants or biologics
later despite increased evidence of increased disease burden.
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that treat a high volume of uveitis cases (primarily ophthal-
mologists) preferred high CTS doses to treat non-infectious
uveitis and did not adhere to currently recommended
guidelines for management of uveitis. Guidelines rec-
ommend the addition of IMS as a steroid-sparing agent
if inflammation cannot be controlled with ≤10 mg/day of
prednisone (or equivalent) within 3 months [8,24]. Add-
itionally, our data showed no change in the treatment dis-
tribution of CTS versus IMS or BIO over 2003 to 2009,
indicating that adoption of the guidelines was slow at
best over this time period. Importantly, CTS therapy
was associated with increases in hospital admissions
and ER visits and all-cause costs. Continued use of CTS
could be due to uncertainty regarding treating severe
inflammation among community ophthalmologists, fear
about side effects or skepticism about efficacy of IMS or
BIO, inexpensive drug costs of CTS, or lack of awareness
of the current guidelines.
This research also provides evidence that IMS and BIO
therapy may be more effective at reducing ophthalmologic
comorbidities related to uveitis than CTS. Further, treat-
ment with BIO was associated with the largest reductions
in non-study drug (i.e., non-biologic) costs and declines
in hospital admissions and ER visits. Most IMS (82%)
patients were never observed to switch to BIO in the
data. Resistance to using biologics may be due to the
lack of clinical trial evidence, the expense of the agents,
perceptions about safety, and a lack of experience with
using biologics.
Though not a focus of the study, we calculated simple
measures of prevalence by counting the patients with
uveitis based on diagnosis codes in 2003 to 2009, only in
2003, and only in 2008. Our simple prevalence estimate,
in terms of patients who ever had a diagnosis of uveitis
using the data, was about 201/100,000; using only those
patients with diagnoses in 2003 and 2008, prevalence
figures were 88 and 113/100,000. Gritz and Wong [13]
estimated that their period prevalence, calculated as the
mid-period prevalence in their one year study in Northern
California, was 115.3 cases/100,000 persons. Reeves et al.
[14] estimated that cumulative prevalence in a Medicare
population of posterior uveitis ranged from 108 to 286/
100,000. Our estimates are generally lower but in the
same range as Reeves et al., potentially because we excluded
patients over age 65 due to dual insurance issues with
private supplemental insurance or Medicare.
Limitations arise from the nature of the administrative
claims data used in this study. Claims data are designed for
billing purposes rather than research, and measurement
error via miscoding of conditions may occur [25,26].
Further, lack of clinical detail in both disease etiology
and severity may lump heterogeneous patient groups
into the same disease category. Further research mayconsider risk adjusting patients at baseline, which was
not performed in this analysis. Patients in our study
treated with CTS are likely to vary significantly in the
severity of their uveitis, and BIO patients had the highest
average Charlson comorbidity index (p = 0.0001 versus
both). Patients receiving both corticosteroids and immu-
nosuppressants are included in this analysis but their
results are not separately broken out from the IMS
group. Future research could examine the subgroups
within our three treated patient samples. Further, we
do not claim that the costs, inpatient or otherwise, in
the paper are uveitis-caused costs. Rather, we describe
costs of patients with uveitis who are on three different
treatments. Accordingly, these costs could be due to
unrelated reasons, potentially related to uveitis, or directly
related to uveitis. Identifying the causality for cost types is
a highly challenging research problem and not something
we set out to do. Nevertheless, these data are appropriate
for studying all-cause costs and utilization, as they con-
tain diagnosis, testing, and procedure information, and
represent payments paid by insurers to providers, and
not charges, for these patients. Finally, claims data are
available for patients with private insurance entering
the healthcare system for treatment and thus capture
only those individuals who have used the health system
and had a claim for services.
Conclusions
This analysis suggests that the burden of uveitis in the US
privately insured population is economically significant.
Patients treated with IMS or BIO were associated with
improvements in rates of ophthalmologic comorbidities as
well as reductions in non-study drug costs. Patients treated
with IMS or BIO were also associated with improvements
in rates of hospital admission and ER visits relative to CTS,
which was associated with increases in these measures.
Given the increase in comorbidity burden associated
with CTS patients in the baseline and study comparison,
there may be evidence that these patients are not ap-
propriately treated.
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